Ivonescimab combined with pemetrexed and carboplatin has been approved for locally advanced or metastatic EGFR mutation–positive NSCLC patients with disease progression after EGFR-TKI therapy (40); however, its use in ALK-TKI–resistant, ALK fusion–positive NSCLC has not been reported. Here, ALK is linked to non-small cell lung carcinoma.